Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
arTreg for immunosuppression withdrawal in liver transplant
NCT03654040Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of darTreg in liver transplant, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number and Severity of Adverse Events Attributed to arTreg. Started Apr 2021; status: terminated.
02
Drugs
darTreg
03
Conditions
liver transplant
Beyond the preview
Go deeper on NCT03654040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03654040.